News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

After Eli Lilly (LLY)'s Flop, Could Alzheimer's Become Healthcare's Trumpshot?



12/1/2016 6:56:16 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
If the healthcare industry’s approach to Alzheimer’s disease were a building project, it could best be described as constructing a skyscraper from the top down–possible, yet at best impractical. Last week Eli Lilly and Company announced that the company’s Alzheimer’s drug solanezumab, which is intended to reduce amyloid plaque, failed to help Alzheimer’s patients recover or maintain their mental acuity in a late-stage trial.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES